NASDAQ:AKTX

Akari Therapeutics - AKTX Stock Forecast, Price & News

$0.57

-0.01 (-1.73%)

(As of 11/25/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.50
▼
$0.58
50-Day Range: $0.40
▼
$0.67
52-Week Range: $0.38
▼
$1.70

Volume: 21,084 shs
Average Volume: 78,811 shs
Market Capitalization: $42.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Akari Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 605.3% Upside
$4.00 Price Target
Short Interest: Healthy
0.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

384th out of 1,044 stocks

Pharmaceutical Preparations Industry

178th out of 508 stocks

3.5

Analyst's Opinion

Consensus Rating
Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Akari Therapeutics has a forecasted upside of 605.3% from its current price of $0.57.
Amount of Analyst Coverage
Akari Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.05% of the outstanding shares of Akari Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Akari Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akari Therapeutics has recently decreased by 44.82%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Akari Therapeutics does not currently pay a dividend.
Dividend Growth
Akari Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AKTX.

2.7

News and Social Media Coverage

News Sentiment
Akari Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Akari Therapeutics this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akari Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.83% of the stock of Akari Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Akari Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akari Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akari Therapeutics has a P/B Ratio of 5.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

November 25, 2022 | money.usnews.com

Akari Therapeutics Plc - ADR

November 23, 2022 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

November 22, 2022 | finance.yahoo.com

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

November 16, 2022 | benzinga.com

Short Volatility Alert: AKARI THERAPEUTICS

November 10, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

November 10, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

November 10, 2022 | finance.yahoo.com

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

November 9, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer

November 9, 2022 | finance.yahoo.com

Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

November 8, 2022 | finance.yahoo.com

Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer

October 31, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference

October 31, 2022 | finance.yahoo.com

Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference

October 29, 2022 | finance.yahoo.com

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

September 27, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

September 27, 2022 | finance.yahoo.com

Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

September 22, 2022 | finance.yahoo.com

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

September 12, 2022 | marketwatch.com

ADRs End Higher, Akari Therapeutics and ArcelorMittal Trade Actively

September 12, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces $12.75 Million Registered Direct Offering

September 12, 2022 | finance.yahoo.com

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

September 8, 2022 | finance.yahoo.com

Akari Therapeutics, Plc (AKTX)

August 2, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Narrows Pipeline Focus

August 1, 2022 | finance.yahoo.com

Akari Therapeutics Narrows Pipeline Focus

July 29, 2022 | finance.yahoo.com

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

July 28, 2022 | finance.yahoo.com

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

July 20, 2022 | finance.yahoo.com

Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings: 9/27/2022
Today: 11/26/2022
Next Earnings (Estimated): 12/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKTX
CUSIP: N/A
CIK: 1541157
Web: www.akaritx.com
Phone: 442080040261
Fax: 646-843-9352
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +605.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -184.76%
Return on Assets: -126.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.73
Quick Ratio: 3.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.11 per share
Price / Book: 5.16

Miscellaneous

Outstanding Shares: 74,449,000
Free Float: 28,440,000
Market Cap: $42.22 million
Optionable: Not Optionable
Beta: 1.28

Key Executives

Dr. Ray Prudo-Chlebosz M.D. (Age 77)
Exec. Chairman
Comp: $618k

Dr. Torsten Hombeck (Age 52)
Chief Financial Officer
Comp: $454.88k

Ms. Rachelle Suzanne Jacques (Age 51)
Pres, CEO & Director

Ms. Melissa Bradford-Klug
Chief Operating Officer

Dr. Miles Nunn
Chief Scientific Officer

Annie Mack
Financial Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings or view top-rated stocks.
What is Akari Therapeutics' stock price forecast for 2023?: 1 analysts have issued 1-year price targets for Akari Therapeutics' shares. Their AKTX share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 605.3% from the stock's current price.
View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts.
How have AKTX shares performed in 2022?: Akari Therapeutics' stock was trading at $1.50 at the start of the year. Since then, AKTX stock has decreased by 62.2% and is now trading at $0.5671.
View the best growth stocks for 2022 here.
When is Akari Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, December 2nd 2022.
View our AKTX earnings forecast.
How were Akari Therapeutics' earnings last quarter?: Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings data on Tuesday, September, 27th. The biopharmaceutical company reported ($0.10) EPS for the quarter.

What other stocks do shareholders of Akari Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).
What is Akari Therapeutics' stock symbol?: Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
Who are Akari Therapeutics' major shareholders?: Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (5.76%) and Omnia Family Wealth LLC (1.05%).
View institutional ownership trends.
How do I buy shares of Akari Therapeutics?: Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Akari Therapeutics' stock price today?: One share of AKTX stock can currently be purchased for approximately $0.57.
How much money does Akari Therapeutics make?: Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $42.22 million. The biopharmaceutical company earns $-17,420,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.
How can I contact Akari Therapeutics?: Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 11/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial